WeVote
Log In

Bill

Bill

HR 3631

VITAL Act of 2025

119th Congress Introduced by Mark Green

Proposed legislation titled VITAL Act would address vaccines in trial settings and potential liability, but specific provisions are not provided in the available summary.

Introduced in House
0
WeVote Research Nonpartisan
Bill Summary · HR 3631

Summary of HR 3631 — VITAL Act of 2025

Official title and purpose (as introduced)

  • Bill Number: HR 3631
  • Short title: The Vaccines in Trial and Liability Act of 2025, also cited as the VITAL Act of 2025.

Notes:
- The available information confirms only the short title and citation language. The full text detailing the bill’s substantive provisions is not provided here.

Legislative actions to date

  • Introduced in the House on May 29, 2025.
  • Referred on May 29, 2025 to:
    • Committee on Energy and Commerce
    • Committee on the Judiciary
    • Referral for a period to be determined by the Speaker, in each case for consideration of provisions within that committee’s jurisdiction.
  • Sponsor: Mark E. Green (primary)

Sponsorship

  • Primary sponsor: Rep. Mark E. Green

What the bill would do (based on available information)

  • The only explicitly available content is the bill’s title and citation. No detailed provisions, sections, or operative text have been provided in the current description.
  • Therefore, the specific policy changes, regulatory framework, liability standards, or funding mechanisms (if any) cannot be stated from the provided text.

Who/what could be affected (unknown from available text)

  • Because substantive provisions are not included, it is not possible to identify specific programs, stakeholders, or statutory regimes that would be directly affected.
  • Potential impacts typically associated with a title involving “Vaccines,” “Trial,” and “Liability” could involve researchers, trial participants, manufacturers, and screening/regulatory processes, but actual effects would depend on the enacted text.

Procedural and timeline considerations

  • Status: Introduced in the House and referred to two committees (Energy and Commerce; Judiciary).
  • Next steps (historically): If reported out of committee, the bill could move to floor consideration in the House, followed by potential action in the Senate. Timelines depend on committee activity and floor scheduling.
  • As introduced, there are no committee reports or floor amendments documented in the provided information.

What to watch for in the full text

  • The exact provisions governing vaccines in trial settings
  • Any liability protections, waivers, or civil liability standards
  • Regulatory oversight, funding, or enforcement mechanisms
  • Definitions of key terms (e.g., “trial,” “vaccine,” “liability”)
  • Interaction with existing federal vaccine or public health laws

If you can share the full text or a summary of the substantive sections, I can provide a detailed, section-by-section analysis and impact assessment.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.